Johnson & Johnson (JNJ) Revenue & Earnings History | Quarter Chart
Income Statement▲
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Cash Flow Statement▲
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Balance Sheet▲
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
Key Metrics▼
Johnson & Johnson (JNJ) quarterly earnings & revenue
Johnson & Johnson (JNJ) is the #22 largest public company in the world by market capitalization, operating in the Drug Manufacturers - General industry.
Johnson & Johnson (JNJ) reported revenue of $25.40B for Q3 2026, up 5.9% year-over-year, with net income of $210.00M and diluted EPS of $0.09.
Over the last four reported quarters, Johnson & Johnson generated $99.33B in revenue and $16.09B in net income.
Johnson & Johnson's next earnings report is scheduled for January 20, 2027 before market open (provider scheduled date). Check the earnings calendar to see all companies reporting this week.
Johnson & Johnson quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q3 2026 | $25.40B | +5.9% | $210.00M | $0.09 |
| Q2 2026 | $25.31B | +6.6% | $5.53B | $2.27 |
| Q1 2026 | $24.06B | +9.9% | $5.24B | $2.14 |
| Q4 2025 | $24.56B | +9.1% | $5.12B | $2.10 |
Compare with other Healthcare companies: Eli Lilly (LLY) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW) · Novartis (NVS)